Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis

Abstract

There was no dose limiting toxicity identified in this study. The suggestion of a symptom response, together with the lack of dose limiting toxicity provide further support for the continued development of this product for the treatment of osteoarthritis.